A
Actinium Pharmaceuticals, Inc.
ATNMCIK 0001388320NYSENon-AcceleratedSmaller ReportingPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
$90.0K
Net Income
$-33.89M
Total Assets
$51.77M
Equity
$7.83M
Shares Out
31.37M
Op. Cash Flow
$-24.58M
Business
Actinium Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted radiotherapies for oncology, focusing on radioconjugates combining tumor biology expertise with radiochemistry. Its pipeline includes solid-tumor candidates ATNM-400 and Actimab-A, hematology programs Iomab-B and Iomab-ACT, and Actimab-A for immune-checkpoint combinations. The company operates across multiple solid and hematologic malignancies via clinical trials at ~50 treatment centers, with planned internal radiopharmaceutical manufacturing and proprietary Ac-225 production technology.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total revenue | 90,000 | — | 81,000 | 1 | 1 | |
| Research and development, net of reimbursements | 21 | 30 | 39 | 23 | 18 | |
| General and administrative | 15 | 12 | 13 | 12 | 8 | |
| Total operating expenses | 36 | 42 | 52 | 35 | 26 | |
| Loss from operations | −36 | −42 | −52 | −34 | −25 | |
| Interest income net | 2 | 4 | 3 | — | — | |
| Total other income | 2 | 4 | 3 | 1 | 190,000 | |
| Net loss | −34 | −38 | −49 | −33 | −25 | |
| Net loss per common share basic (in Dollars per share) | −1.09 | −1.27 | −1.83 | −1.37 | −1.2 | |
| Net loss per common share diluted (in Dollars per share) | −1.09 | −1.27 | −1.83 | −1.37 | −1.2 | |
| Weighted average common shares outstanding basic (in Shares) | 31 | 30 | 27 | 24 | 21 | |
| Weighted average common shares outstanding diluted (in Shares) | 31 | 30 | 27 | 24 | 21 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 48 | 73 | 77 | 109 | 78 | |
| Prepaid expenses and other current assets | 1 | 2 | 2 | 2 | 1 | |
| Total Current Assets | 49 | 75 | 78 | 111 | 80 | |
| Property and equipment, net of accumulated depreciation of $1,064 and $891 | 295,000 | 364,000 | 550,000 | 604,000 | 340,000 | |
| Restricted cash long term | 335,000 | 324,000 | 313,000 | 302,000 | — | |
| Operating lease right-of-use assets | 2 | 2 | 2 | 2 | 241,000 | |
| Finance leases right-of-use assets | 10,000 | 20,000 | 30,000 | 3,000 | 58,000 | |
| Total Assets | 52 | 77 | 81 | 114 | 80 | |
| Accounts payable and accrued expenses | 7 | 8 | 8 | — | — | |
| Operating leases current liability | 711,000 | 569,000 | 530,000 | 494,000 | 245,000 | |
| Finance leases current liability | 11,000 | 11,000 | 11,000 | 4,000 | 62,000 | |
| Total Current Liabilities | 8 | 8 | 8 | 11 | 7 | |
| Long-term license revenue deferred | 35 | 35 | 35 | — | — | |
| Long-term operating lease obligations | 972,000 | 984,000 | 2 | 2 | — | |
| Long-term finance lease obligations | — | 9,000 | 19,000 | — | 3,000 | |
| Total Liabilities | 44 | 44 | 45 | 48 | 7 | |
| Commitments and contingencies | — | — | — | — | — | |
| Preferred stock, $0.001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding | — | — | — | — | — | |
| Common stock, $0.001 par value; 1,000,000,000 shares authorized; 31,195,891 shares issued and outstanding at December 31, 2025 and 2024, respectively | 31,000 | 31,000 | 28,000 | 26,000 | 22,000 | |
| Additional paid-in capital | 418 | 409 | 374 | 355 | 329 | |
| Accumulated other comprehensive loss | −20,000 | — | — | — | — | |
| Accumulated deficit | −410 | −376 | −338 | −289 | −256 | |
| Total Stockholders Equity | 8 | 33 | 36 | 66 | 74 | |
| Total Liabilities and Stockholders Equity | 52 | 77 | 81 | 114 | 80 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Stock-based compensation expense | 9 | 5 | 4 | 3 | 2 | |
| Depreciation expense | 173,000 | 197,000 | — | — | — | |
| Amortization of right-of-use assets | 648,000 | 614,000 | 583,000 | — | — | |
| Prepaid expenses and other current assets | 219,000 | −15,000 | 49,000 | −158,000 | −161,000 | |
| Accounts payable and accrued expenses | −346,000 | −387,000 | −2 | 5 | 1 | |
| Operating lease liabilities | −577,000 | −530,000 | −494,000 | −272,000 | — | |
| Net Cash Used In Operating Activities | −25 | −33 | −47 | 9 | −21 | |
| Purchase of property and equipment | −104,000 | −11,000 | −153,000 | −366,000 | −133,000 | |
| Net Cash Used In Investing Activities | −104,000 | −11,000 | −153,000 | −366,000 | −133,000 | |
| Payments on finance leases | −10,000 | −9,000 | −4,000 | −49,000 | −85,000 | |
| Proceeds from sales of shares of common stock, net of offering costs | — | 29 | 15 | 23 | 35 | |
| Restricted stock units withheld to cover tax obligations | −207,000 | — | — | — | — | |
| Proceeds from the exercise of stock options | — | 75,000 | 262,000 | — | 6,000 | |
| Net Cash (Used In) Provided By Financing Activities | −217,000 | 29 | 15 | 23 | 35 | |
| Effect of foreign currency rates on cash | 6,000 | — | — | — | — | |
| Net Change in Cash, Cash Equivalents and Restricted Cash | −25 | −4 | — | 31 | 14 | |
| Right-of-use assets obtained in exchange for lease liabilities | 708,000 | — | 30,000 | 3 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Actinium Pharmaceuticals, Inc.'s CIK number?
Actinium Pharmaceuticals, Inc.'s SEC CIK number is 0001388320 (1388320). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Actinium Pharmaceuticals, Inc.'s SEC filings?
All of Actinium Pharmaceuticals, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.